MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Arcutis Biotherapeutics Inc

Închisă

SectorSănătate

21.14 3.48

Rezumat

Modificarea prețului

24h

Curent

Minim

20.29

Maxim

21.53

Indicatori cheie

By Trading Economics

Venit

9.2M

-16M

Vânzări

16M

82M

Marjă de profit

-19.491

Angajați

342

EBITDA

6.7M

-12M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+10.79% upside

Dividende

By Dow Jones

Următoarele câștiguri

28 oct. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

502M

2.2B

Deschiderea anterioară

17.66

Închiderea anterioară

21.14

Sentimentul știrilor

By Acuity

17%

83%

28 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 oct. 2025, 16:58 UTC

Câștiguri

BMW Trims 2025 View, Citing Weaker Performance in China

7 oct. 2025, 23:43 UTC

Market Talk

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 oct. 2025, 23:36 UTC

Market Talk

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 oct. 2025, 23:19 UTC

Market Talk

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 oct. 2025, 22:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 oct. 2025, 22:50 UTC

Market Talk

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 oct. 2025, 22:40 UTC

Market Talk

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 oct. 2025, 21:56 UTC

Market Talk

Global Equities Roundup: Market Talk

7 oct. 2025, 21:56 UTC

Market Talk

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 oct. 2025, 20:44 UTC

Acțiuni populare

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 oct. 2025, 19:42 UTC

Market Talk

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 oct. 2025, 19:23 UTC

Achiziții, Fuziuni, Preluări

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 oct. 2025, 19:07 UTC

Market Talk

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 oct. 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 oct. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7 oct. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 oct. 2025, 16:20 UTC

Market Talk

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 oct. 2025, 16:15 UTC

Market Talk

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 oct. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 oct. 2025, 15:37 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 oct. 2025, 15:37 UTC

Market Talk

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 oct. 2025, 15:33 UTC

Market Talk

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 oct. 2025, 15:25 UTC

Market Talk

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 oct. 2025, 15:15 UTC

Market Talk

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 oct. 2025, 15:04 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7 oct. 2025, 15:04 UTC

Market Talk

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 oct. 2025, 14:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 oct. 2025, 14:56 UTC

Market Talk

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 oct. 2025, 14:52 UTC

Câștiguri

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Comparație

Modificare preț

Arcutis Biotherapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

10.79% sus

Prognoză pe 12 luni

Medie 22.79 USD  10.79%

Maxim 29 USD

Minim 14.29 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArcutis Biotherapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

7

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

12.42 / 14.93Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

28 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
help-icon Live chat